Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381262 | 1.00 | KDM4E (0.57) | KDM4EL3MBTL1NCF1LOXL2NCOA1 | |
| Hydrochloric Acid SCHEMBL4381713 | 0.98 | KDM4E (0.56) | KDM4EL3MBTL1NCF1LOXL2NCOA1 | |
| Acetic Acid SCHEMBL29071419 | 0.93 | KDM4E (0.54) | KDM4EL3MBTL1NCF1LOXL2NCOA1 | |
| Quinoline SCHEMBL28100425 | 0.90 | ALDH1A1 (0.53) | KDM4EL3MBTL1NCF1LOXL2NCOA1 | |
| Trifluoroacetic Acid SCHEMBL28146694 | 0.89 | L3MBTL1 (0.64) | KDM4EL3MBTL1NCF1LOXL2NCOA1 | |
| SCHEMBL8221166 | 0.87 | PARP1 (0.56) | KDM4EL3MBTL1KMT2ANSD2PDE4B | |
| SCHEMBL1804352 | 0.87 | PARP1 (0.56) | KDM4EL3MBTL1KMT2ANSD2PDE4B | |
| SCHEMBL23193358 | 0.84 | NCF1 (0.50) | KDM4ENCF1LOXL2HDAC3HDAC4 | |
| Quinoline SCHEMBL28140561 | 0.83 | PARP1 (0.57) | KDM4EL3MBTL1NCOA1NCOA3KMT2A | |
| Hydrazine SCHEMBL27689567 | 0.83 | KDM4E (0.53) | KDM4EL3MBTL1NCF1LOXL2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543869-B1 | N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-05-27 | — | — | EP | claimed |
| US-12509439-B2 | Anti-malarial agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | claimed |
| WO-2025118255-A1 | RADIOLABELED FAPI COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京师范大学 | 2025-06-12 | — | — | WO | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| EP-4543878-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | Astrazeneca AB (SE) | 2025-04-30 | — | — | EP | claimed |
| CN-119562951-A | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2025027117-A1 | CARBOXAMIDE-4-QUINOLINE COMPOUNDS WITH ANTHELMINTIC ACTIVITY | INTERVET INTERNATIONAL B.V. (NL) | 2025-02-06 | — | — | WO | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| US-20240139350-A1 | RADIOACTIVELY LABELED LIGAND FOR FIBROBLAST ACTIVATION PROTEIN-ALPHA IMAGING AGENT AND PREPARATION METHOD THEREFOR | FIVE ELEVEN PHARMA, INC | 2024-05-02 | — | — | US | claimed |
| CN-101146810-A | Method for making 1-substituted 1H-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor | FERRER INT (ES) | 2008-03-19 | — | — | CN | claimed |
| EP-1879893-A1 | METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR | FERRER INTERNACIONAL, S.A. (ES) | 2008-01-23 | — | — | EP | claimed |
| CN-101052386-A | Medicine composition for pediatric use based on nk2 antagonist | GUIDOTTI LAB S P A (IT) | 2007-10-10 | — | — | CN | claimed |
| CN-101023071-A | New heterocyclic amides | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | claimed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2007012900-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-02-01 | — | — | WO | claimed |
| WO-2006100226-A1 | METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-28 | — | — | WO | claimed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| CN-1092642-C | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 2002-10-16 | — | — | CN | claimed |
| CN-1156451-A | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 1997-08-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509439-B2 | Anti-malarial agents | RCC1, PFN1, NHERF1 | KDM4E 3704/4885L3MBTL1 3793/4885NCF1 331/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | KDM4E 3828/4885L3MBTL1 1518/4885NCF1 750/4885 |
| US-20240139350-A1 | RADIOACTIVELY LABELED LIGAND FOR FIBROBLAST ACTIVATION PROTEIN-ALPHA IMAGING AGENT AND PREPARATION METHOD THEREFOR | FAP, FIBP, FGFR1 | KDM4E 4716/4885L3MBTL1 4086/4885NCF1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.